This free whitepaper explores a novel approach to extracting insights from how patients use metaphorical language. In it, we demonstrate how linguistic analysis can decode metaphors to provide generalizable insight and how unorthodox lines of questioning can obtain more authentic responses than those the market research community traditionally uses.

In this whitepaper, we explore the following topics:

• The power of ubiquitous, familiar metaphors and figurative language
• How conventional question design traps patients into giving compelling but inaccurate stories
• The use of novel questions and methods to produce more authentic and resonant stories

In this whitepaper, you’ll see how patients in various stages of their therapeutic journey communicate experiences differently and why understanding those language patterns is crucial to addressing their needs.

Explore the following topics:

• Disconnects between what patients experience and what they share with their physicians
• The natural lexicon of "bad days" and "good days" in RA
• How the language of RA changes over the patient's journey

More than physicians, nurses, or payers, hospital pharmacists are closest to issues related to biosimilars and can provide a broad perspective on this subject. In February 2018, inVibe fielded an open-ended, eight-question survey to Hospital Pharmacy Directors and Associate Directors responsible for making formulary recommendations, including purchasing, acquiring, and dispensing biosimilars.

The study objective was to understand how hospital pharmacists currently perceive and utilize biosimilars in comparison to the originators’ corresponding biological products.

With the possible exception of breast cancer, biomarker testing is more established in non-small cell lung cancer (NSCLC) than in other oncology indications. If you believe that NSCLC biomarker testing is fully standardized, you would be wrong. Our survey respondents taught us that we are only at the end of the beginning of standardization of NSCLC biomarker testing.

Explore the following topics:

• Biomarkers mentioned in the study: ALK, BRAF, EGFR, HER2, KRAS, PD-L1, ROS1, T790M, and next generation sequencing
• NSCLC treatments mentioned in the study: afatinib (Gilotrif), atezolizumab (Tecentriq), chemotherapy, crizotinib (Xalkori), dabrafnib (Tafinlar), erlotinib (Tarceva), gefitinib (Iressa), nivolumab (Opdivo), osimertinib (Tagrisso), pembrolizumab (Keytruda), pemetrexed (Alimta), trametinib (Mekinst)
• Current challenges and suggested improvements in NSCLC biomarker testing

This free whitepaper demonstrates how new technologies have reduced the barriers to gathering rich qualitative insights, and why this is important to decision-makers.

Explore the following topics:

• Comparison of prevailing research methodologies
• Keys to establishing data quality for qualitative research
• Consequences of the increasing reliance on web surveys
• Ways to maximize participant response
• How technology can disrupt the qualitative research process